EP0197901A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
Assignee: Swedish Orphan Biovitrum AB
•
Filing: 1986-02-24
•
Granted: —
•
Expires: 2006-02-24
Abstract
Abstract Novel, biologically active fragments of human anti- hemophilic factor, processes for their preparation, pharmaceutical preparations containing them and the use of such fragments in the treatment of patients suffering from haemophilia.
Inventors
- 👤 Lars-Olof Andersson
- 👤 Nanna Forsman
- 👤 Kerstin Ebba Ingrid Larsen
- 👤 Annelie Birgitta Lundin
- 👤 Bohdan Pavlu
- 👤 Inga Helena Sandberg
- 👤 Karin Margareta Sewerin
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 23:42
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61P; A61P7/00; A61P7/04; E; E02; E02D; E02D31/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83; Y10S930/00; Y10S930/01; Y10S930/10
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
39 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 90 000 daltons and 80 000 daltons, respectively and having the aminoterminal amino acid sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively and having the aminoacid composition:
Claim 2
Dependent Claim
39 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 90 000 daltons and 80 000 daltons, respectively and having the aminoterminal amino acid sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively and having the aminoacid composition:
Claim 3
Dependent Claim
37 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weight 115 000 daltons and 80 000 daltons, respectively and having the aminoterminal sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively and having the aminoacid composition:
Claim 4
Dependent Claim
37 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weight 115 000 daltons and 80 000 daltons, respectively and having the aminoterminal sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively and having the aminoacid composition:
Claim 5
Dependent Claim
37 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weight 130 000 daltons and 80 000 daltons, respectively and having the aminoerminal aminoacid sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively and the aminoacid composition:
Claim 6
Dependent Claim
37 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weight 130 000 daltons and 80 000 daltons, respectively and having the aminoerminal aminoacid sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively and the aminoacid composition:
Claim 7
Dependent Claim
36 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 150 000 daltons and 80 000 daltons, respectively, and having the aminoterminal sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively, and the aminoacid composition:
Claim 8
Dependent Claim
36 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 150 000 daltons and 80 000 daltons, respectively, and having the aminoterminal sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively, and the aminoacid composition:
Claim 9
Dependent Claim
36 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 160 000 daltons and 80 000 daltons, respectively, and having the aminoterminal sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively, and the aminoacid composition:
Claim 10
Dependent Claim
36 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 160 000 daltons and 80 000 daltons, respectively, and having the aminoterminal sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively, and the aminoacid composition:
Claim 11
Dependent Claim
37 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 180 000 daltons and 80 000 daltons, respectively, and having the aminoterminal aminoacid sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively, and the aminoacid composition:
Claim 12
Dependent Claim
37 words
Active fragment of human Factor VIII characterized by containing two peptide chains having molecular weights 180 000 daltons and 80 000 daltons, respectively, and having the aminoterminal aminoacid sequences Ala-Thr-Arg-Arg-Tyr-Tyr- and Glu-Ile-Thr-Arg-Thr-Thr-, respectively, and the aminoacid composition:
Claim 13
Dependent Claim
18 words
A pharmaceutical preparation containing as an active ingredient a Factor VIII fragment according to any of claims 1-6.
Claim 14
Dependent Claim
20 words
An active fragment of human Factor VIII according to any of claims 1-6 for use in the treatment of haemophilia.
Claim 15
Dependent Claim
21 words
An active fragment of human Factor VIII according to any of claims 1-6 for use in normalizing hemostasis in haemophilic patients.
Claim 16
Dependent Claim
47 words
A process for the preparation of a Factor VIII fragment according to any of claims 1-6, characterized in that fragmented Factor VIII containing material is separated using an anion exchange matrix optionally containing covalently bound antibodies against von Willebrand Factor, using salt gradient elution at pH 6-8.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.